<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01895855</url>
  </required_header>
  <id_info>
    <org_study_id>PXVX-VC-200-003</org_study_id>
    <nct_id>NCT01895855</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera</brief_title>
  <official_title>A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Efficacy Trial of a Single Dose Live Oral Cholera Vaccine, PXVX0200 CVD 103-HgR, in Preventing Cholera Following Challenge With Vibrio Cholerae 10 Days or 3 Months After Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emergent BioSolutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emergent BioSolutions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if PXVX0200 is safe and effective in preventing&#xD;
      cholera infection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Efficacy Trial of a Single Dose of&#xD;
      Live Oral Cholera Vaccine Candidate, PXVX0200 CVD 103-HgR Strain, in Preventing Cholera&#xD;
      following Challenge with Vibrio cholerae O1 El Tor Inaba 10 Days or 3 Months after&#xD;
      Vaccination in volunteers aged 18-45 years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% of Participants With Moderate to Severe Diarrhea</measure>
    <time_frame>Ten days after vaccination</time_frame>
    <description>Determine whether a single dose of PXVX0200 provides significantly greater protection than placebo against a challenge with virulent V. cholerae O1 El Tor Inaba at 10 days after vaccination. The primary endpoint was the occurrence of moderate or severe (&gt;/= 3 liters) diarrhea.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>% of Participants With Moderate to Severe Diarrhea</measure>
    <time_frame>Ninety days after vaccination</time_frame>
    <description>Determine whether a single dose of PXVX0200 provides significant greater protection than placebo against a challenge with virulent V. cholerae O1 El Tor Inaba at 3 months after vaccination. The primary endpoint was the occurrence of moderate or severe (&gt;/= 3 liters) of diarrhea.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Weight of Diarrheal Stools Following the 10 Day Cholera Challenge</measure>
    <time_frame>Through 10 Days following challenge</time_frame>
    <description>Total weight (converted to volume) per subject of diarrheal stools measured from subjects with diarrhea following the 10 day cholera challenge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Weight of Diarrheal Stools Following the 90 Day Cholera Challenge</measure>
    <time_frame>Through 10 Days following challenge</time_frame>
    <description>Total weight (converted to volume) per subject of diarrheal stools measured from subjects with diarrhea following the 90 day cholera challenge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of Participants With Diarrhea of Any Severity Following a 10 Day Cholera Challenge</measure>
    <time_frame>Through 10 Days following challenge</time_frame>
    <description>Incidence of mild or worse (any severity) diarrhea following the 10 day cholera challenge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of Participants With Diarrhea of Any Severity Following a 90 Day Challenge</measure>
    <time_frame>Through 10 Days following challenge</time_frame>
    <description>Incidence of mild or worse (any severity) diarrhea following the 90 day cholera challenge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of Participants With Fever Following the 10 Day Cholera Challenge</measure>
    <time_frame>Through 10 Days following challenge</time_frame>
    <description>Incidence of mild or worse fever following the 10 day cholera challenge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of Participants With Fever Following the 90 Day Cholera Challenge</measure>
    <time_frame>Through 10 Days following challenge</time_frame>
    <description>Incidence of mild or worse fever following the 90 day cholera challenge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Fecal Shedding Following 10 Day Challenge</measure>
    <time_frame>Through 10 Days post challenge</time_frame>
    <description>Number of days of fecal shedding of wild type V. cholerae following 10 Day Challenge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Fecal Shedding Following 90 Day Challenge</measure>
    <time_frame>Through 10 days following challenge</time_frame>
    <description>Number of days of fecal shedding of wild type V. cholerae following 90 Day Challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure># of Days With Positive Stool Culture Following 10 Day Cholera Challenge</measure>
    <time_frame>Through 10 Days following challenge</time_frame>
    <description>Total number of days with a positive stool culture following the 10 Day Cholera challenge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure># of Days With Positive Stool Culture Following 90 Day Cholera Challenge</measure>
    <time_frame>Through 10 Days following challenge</time_frame>
    <description>Total number of days with a positive stool culture following 90 Day Cholera Challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of Participants With Reactogenicity, Diarrhea, Fever or Unsolicited Adverse Events Following Vaccination</measure>
    <time_frame>Following vaccination (Days 1 - 8) and to Day 29</time_frame>
    <description>Incidence and severity of signs and symptoms of reactogenicity such as diarrhea, and fever following vaccination (through Day 8).&#xD;
Incidence and severity of unsolicited adverse events following vaccination (through Day 29).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Cholera</condition>
  <arm_group>
    <arm_group_label>PXVX0200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 5x10^8 CFU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Biological: Placebo physiological saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PXVX0200</intervention_name>
    <description>Single dose; liquid suspension after reconstitution with buffer; 5x10^8</description>
    <arm_group_label>PXVX0200</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy men or women,&#xD;
&#xD;
          -  age 18 to 45 years inclusive;&#xD;
&#xD;
          -  normal medical history and physical examination; and&#xD;
&#xD;
          -  no clinically significant abnormalities from:&#xD;
&#xD;
          -  urine dipstick for glucose, protein, and blood&#xD;
&#xD;
          -  complete blood count,&#xD;
&#xD;
          -  serum hepatic transaminases,&#xD;
&#xD;
          -  total bilirubin (direct if abnormal),&#xD;
&#xD;
          -  creatinine,&#xD;
&#xD;
          -  electrolytes,&#xD;
&#xD;
          -  albumin, or&#xD;
&#xD;
          -  electrocardiogram.&#xD;
&#xD;
          -  Women must have a negative pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  travel to a cholera endemic area in the previous 5 years;&#xD;
&#xD;
          -  abnormal stool pattern or regular use of laxatives;&#xD;
&#xD;
          -  history of eating disorders (such as bulimia), anal or rectal disorders, allergy to&#xD;
             tetracycline and/or ciprofloxacin;&#xD;
&#xD;
          -  history of cholera or enterotoxigenic E. coli challenge or infection;&#xD;
&#xD;
          -  current or recent antibiotic use;&#xD;
&#xD;
          -  pregnancy or nursing;&#xD;
&#xD;
          -  positive serology for HIV, hepatitis B antigen, or hepatitis C;&#xD;
&#xD;
          -  any immunosuppressive medical condition;&#xD;
&#xD;
          -  history of hospitalization for psychiatric illness or use of specific psychiatric&#xD;
             drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James McCarty, MD</last_name>
    <role>Study Director</role>
    <affiliation>Emergent BioSolutions</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children'S Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Chen WH, Cohen MB, Kirkpatrick BD, Brady RC, Galloway D, Gurwith M, Hall RH, Kessler RA, Lock M, Haney D, Lyon CE, Pasetti MF, Simon JK, Szabo F, Tennant S, Levine MM. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor. Clin Infect Dis. 2016 Jun 1;62(11):1329-1335. doi: 10.1093/cid/ciw145. Epub 2016 Mar 21.</citation>
    <PMID>27001804</PMID>
  </results_reference>
  <results_reference>
    <citation>Haney DJ, Lock MD, Gurwith M, Simon JK, Ishioka G, Cohen MB, Kirkpatrick BD, Lyon CE, Chen WH, Sztein MB, Levine MM, Harris JB. Lipopolysaccharide-specific memory B cell responses to an attenuated live cholera vaccine are associated with protection against Vibrio cholerae infection. Vaccine. 2018 May 11;36(20):2768-2773. doi: 10.1016/j.vaccine.2018.04.011. Epub 2018 Apr 11.</citation>
    <PMID>29655627</PMID>
  </results_reference>
  <results_reference>
    <citation>Haney DJ, Lock MD, Simon JK, Harris J, Gurwith M. Antibody-Based Correlates of Protection Against Cholera Analysis of a Challenge Study in a Cholera-Naïve Population. Clin Vaccine Immunol. 2017 May 31. pii: CVI.00098-17. doi: 10.1128/CVI.00098-17. [Epub ahead of print]</citation>
    <PMID>28566334</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 5, 2013</study_first_submitted>
  <study_first_submitted_qc>July 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2013</study_first_posted>
  <results_first_submitted>July 5, 2018</results_first_submitted>
  <results_first_submitted_qc>March 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 1, 2021</results_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholera</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PXVX0200</title>
          <description>Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 2x10^8 to 2x10^9 CFU in a liquid suspension</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Biological: Placebo physiological saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PXVX0200</title>
          <description>Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 2x10^8 to 2x10^9 CFU in a liquid suspension</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Biological: Placebo physiological saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="95"/>
            <count group_id="B2" value="102"/>
            <count group_id="B3" value="197"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="197"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.5" lower_limit="18" upper_limit="45"/>
                    <measurement group_id="B2" value="30.6" lower_limit="18" upper_limit="45"/>
                    <measurement group_id="B3" value="31.0" lower_limit="18" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="186"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>% of Participants With Moderate to Severe Diarrhea</title>
        <description>Determine whether a single dose of PXVX0200 provides significantly greater protection than placebo against a challenge with virulent V. cholerae O1 El Tor Inaba at 10 days after vaccination. The primary endpoint was the occurrence of moderate or severe (&gt;/= 3 liters) diarrhea.</description>
        <time_frame>Ten days after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PXVX0200</title>
            <description>Biological: PXVX0200&#xD;
Single dose; liquid suspension after reconstitution with buffer; 5x10^8 CFU</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Biological: Placebo physiological saline</description>
          </group>
        </group_list>
        <measure>
          <title>% of Participants With Moderate to Severe Diarrhea</title>
          <description>Determine whether a single dose of PXVX0200 provides significantly greater protection than placebo against a challenge with virulent V. cholerae O1 El Tor Inaba at 10 days after vaccination. The primary endpoint was the occurrence of moderate or severe (&gt;/= 3 liters) diarrhea.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7"/>
                    <measurement group_id="O2" value="59.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>35 participants were challenged 10 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The lower, two sided 95% confidence bound on protective efficacy must be &gt;/= 30%.</non_inferiority_desc>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>90.3</param_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>62.7</ci_lower_limit>
            <estimate_desc>Confidence intervals for the protective vaccine efficacy (PE) estimates were calculated using the method of Farrington and Manning (Farrington 1990).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>% of Participants With Moderate to Severe Diarrhea</title>
        <description>Determine whether a single dose of PXVX0200 provides significant greater protection than placebo against a challenge with virulent V. cholerae O1 El Tor Inaba at 3 months after vaccination. The primary endpoint was the occurrence of moderate or severe (&gt;/= 3 liters) of diarrhea.</description>
        <time_frame>Ninety days after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PXVX0200</title>
            <description>Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 2x10^8 to 2x10^9 CFU in a liquid suspension</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Biological: Placebo physiological saline</description>
          </group>
        </group_list>
        <measure>
          <title>% of Participants With Moderate to Severe Diarrhea</title>
          <description>Determine whether a single dose of PXVX0200 provides significant greater protection than placebo against a challenge with virulent V. cholerae O1 El Tor Inaba at 3 months after vaccination. The primary endpoint was the occurrence of moderate or severe (&gt;/= 3 liters) of diarrhea.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1"/>
                    <measurement group_id="O2" value="59.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>33 participants were challenged 90 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The lower, two sided 95% confidence bound on protective efficacy must be &gt;/= 30%.</non_inferiority_desc>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>79.5</param_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>49.9</ci_lower_limit>
            <estimate_desc>Confidence intervals for the protective vaccine efficacy (PE) estimates were calculated using the method of Farrington and Manning (Farrington 1990).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Weight of Diarrheal Stools Following the 10 Day Cholera Challenge</title>
        <description>Total weight (converted to volume) per subject of diarrheal stools measured from subjects with diarrhea following the 10 day cholera challenge.</description>
        <time_frame>Through 10 Days following challenge</time_frame>
        <population>Intent to Treat population comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>PXVX0200</title>
            <description>Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 5x10^8 CFU</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Biological: Placebo physiological saline</description>
          </group>
        </group_list>
        <measure>
          <title>Total Weight of Diarrheal Stools Following the 10 Day Cholera Challenge</title>
          <description>Total weight (converted to volume) per subject of diarrheal stools measured from subjects with diarrhea following the 10 day cholera challenge.</description>
          <population>Intent to Treat population comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.</population>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309" lower_limit="154" upper_limit="18164"/>
                    <measurement group_id="O2" value="4524" lower_limit="140" upper_limit="24374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>35 participants were challenged 10 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0073</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Weight of Diarrheal Stools Following the 90 Day Cholera Challenge</title>
        <description>Total weight (converted to volume) per subject of diarrheal stools measured from subjects with diarrhea following the 90 day cholera challenge.</description>
        <time_frame>Through 10 Days following challenge</time_frame>
        <population>Intent to Treat population comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>PXVX0200</title>
            <description>Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 5x10^8 CFU</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Biological: Placebo physiological saline</description>
          </group>
        </group_list>
        <measure>
          <title>Total Weight of Diarrheal Stools Following the 90 Day Cholera Challenge</title>
          <description>Total weight (converted to volume) per subject of diarrheal stools measured from subjects with diarrhea following the 90 day cholera challenge.</description>
          <population>Intent to Treat population comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.</population>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="603" lower_limit="22" upper_limit="9950"/>
                    <measurement group_id="O2" value="4524" lower_limit="140" upper_limit="24374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>33 participants were challenge 90 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% of Participants With Diarrhea of Any Severity Following a 10 Day Cholera Challenge</title>
        <description>Incidence of mild or worse (any severity) diarrhea following the 10 day cholera challenge.</description>
        <time_frame>Through 10 Days following challenge</time_frame>
        <population>Intent to treat population comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>PXVX0200</title>
            <description>Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 5x10^8 CFU</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Biological: Placebo physiological saline</description>
          </group>
        </group_list>
        <measure>
          <title>% of Participants With Diarrhea of Any Severity Following a 10 Day Cholera Challenge</title>
          <description>Incidence of mild or worse (any severity) diarrhea following the 10 day cholera challenge.</description>
          <population>Intent to treat population comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.</population>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="92.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>35 participants were challenged 10 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>84.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>67.0</ci_lower_limit>
            <ci_upper_limit>100.0</ci_upper_limit>
            <estimate_desc>Confidence interval for the protective vaccine efficacy (PE) estimates were calculated using the method of Farrington and Manning (Farrington 1990).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% of Participants With Diarrhea of Any Severity Following a 90 Day Challenge</title>
        <description>Incidence of mild or worse (any severity) diarrhea following the 90 day cholera challenge.</description>
        <time_frame>Through 10 Days following challenge</time_frame>
        <population>Intent to treat population comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>PXVX0200</title>
            <description>Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 5x10^8 CFU</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Biological: Placebo physiological saline</description>
          </group>
        </group_list>
        <measure>
          <title>% of Participants With Diarrhea of Any Severity Following a 90 Day Challenge</title>
          <description>Incidence of mild or worse (any severity) diarrhea following the 90 day cholera challenge.</description>
          <population>Intent to treat population comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.</population>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5"/>
                    <measurement group_id="O2" value="92.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>33 participants were challenged 90 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>50.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>33.6</ci_lower_limit>
            <ci_upper_limit>66.8</ci_upper_limit>
            <estimate_desc>Confidence interval for protective vaccine efficacy (PE) estimates were calculated using the method of Farrington and Manning (Farrington 1990).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% of Participants With Fever Following the 10 Day Cholera Challenge</title>
        <description>Incidence of mild or worse fever following the 10 day cholera challenge.</description>
        <time_frame>Through 10 Days following challenge</time_frame>
        <population>Intent to treat population comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>PXVX0200</title>
            <description>Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 5x10^8 CFU</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Biological: Placebo physiological saline</description>
          </group>
        </group_list>
        <measure>
          <title>% of Participants With Fever Following the 10 Day Cholera Challenge</title>
          <description>Incidence of mild or worse fever following the 10 day cholera challenge.</description>
          <population>Intent to treat population comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.</population>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>35 participants were challenged 10 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0025</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% of Participants With Fever Following the 90 Day Cholera Challenge</title>
        <description>Incidence of mild or worse fever following the 90 day cholera challenge.</description>
        <time_frame>Through 10 Days following challenge</time_frame>
        <population>Intent to treat population comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>PXVX0200</title>
            <description>Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 5x10^8 CFU</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Biological: Placebo physiological saline</description>
          </group>
        </group_list>
        <measure>
          <title>% of Participants With Fever Following the 90 Day Cholera Challenge</title>
          <description>Incidence of mild or worse fever following the 90 day cholera challenge.</description>
          <population>Intent to treat population comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.</population>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1"/>
                    <measurement group_id="O2" value="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>33 participants were challenged 90 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0159</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Fecal Shedding Following 10 Day Challenge</title>
        <description>Number of days of fecal shedding of wild type V. cholerae following 10 Day Challenge.</description>
        <time_frame>Through 10 Days post challenge</time_frame>
        <population>Intent to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>PXVX0200</title>
            <description>Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 2x10^8 to 2x10^9 CFU in a liquid suspension</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Biological: Placebo physiological saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Fecal Shedding Following 10 Day Challenge</title>
          <description>Number of days of fecal shedding of wild type V. cholerae following 10 Day Challenge.</description>
          <population>Intent to treat (ITT) population</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="3.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>35 participants were challenged 10 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Fecal Shedding Following 90 Day Challenge</title>
        <description>Number of days of fecal shedding of wild type V. cholerae following 90 Day Challenge</description>
        <time_frame>Through 10 days following challenge</time_frame>
        <population>Intent to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>PXVX0200</title>
            <description>Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 2x10^8 to 2x10^9 CFU in a liquid suspension</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Biological: Placebo physiological saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Fecal Shedding Following 90 Day Challenge</title>
          <description>Number of days of fecal shedding of wild type V. cholerae following 90 Day Challenge</description>
          <population>Intent to treat (ITT) population</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="3.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>33 participants were challenged 90 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title># of Days With Positive Stool Culture Following 10 Day Cholera Challenge</title>
        <description>Total number of days with a positive stool culture following the 10 Day Cholera challenge.</description>
        <time_frame>Through 10 Days following challenge</time_frame>
        <population>Intent to treat (ITT) comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>PVXV0200</title>
            <description>Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Biological: Placebo physiological saline</description>
          </group>
        </group_list>
        <measure>
          <title># of Days With Positive Stool Culture Following 10 Day Cholera Challenge</title>
          <description>Total number of days with a positive stool culture following the 10 Day Cholera challenge.</description>
          <population>Intent to treat (ITT) comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.20"/>
                    <measurement group_id="O2" value="3.3" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>35 participants were challenged 10 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title># of Days With Positive Stool Culture Following 90 Day Cholera Challenge</title>
        <description>Total number of days with a positive stool culture following 90 Day Cholera Challenge</description>
        <time_frame>Through 10 Days following challenge</time_frame>
        <population>Intent to treat (ITT) comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>PVXV0200</title>
            <description>Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Biological: Placebo physiological saline</description>
          </group>
        </group_list>
        <measure>
          <title># of Days With Positive Stool Culture Following 90 Day Cholera Challenge</title>
          <description>Total number of days with a positive stool culture following 90 Day Cholera Challenge</description>
          <population>Intent to treat (ITT) comprising all subjects who were randomized and received either PXVX0200 vaccine or placebo.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.41"/>
                    <measurement group_id="O2" value="3.3" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>33 participants were challenged 90 days after receiving PXVX0200. 66 participants were challenged either 10 days or 90 days after receiving placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% of Participants With Reactogenicity, Diarrhea, Fever or Unsolicited Adverse Events Following Vaccination</title>
        <description>Incidence and severity of signs and symptoms of reactogenicity such as diarrhea, and fever following vaccination (through Day 8).&#xD;
Incidence and severity of unsolicited adverse events following vaccination (through Day 29).</description>
        <time_frame>Following vaccination (Days 1 - 8) and to Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PVXV0200</title>
            <description>Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 2x10^8 to 2x10^9 CFU in a liquid suspension</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Biological: Placebo physiological saline</description>
          </group>
        </group_list>
        <measure>
          <title>% of Participants With Reactogenicity, Diarrhea, Fever or Unsolicited Adverse Events Following Vaccination</title>
          <description>Incidence and severity of signs and symptoms of reactogenicity such as diarrhea, and fever following vaccination (through Day 8).&#xD;
Incidence and severity of unsolicited adverse events following vaccination (through Day 29).</description>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% of Subjects with Reactogenicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.5"/>
                    <measurement group_id="O2" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of Subjects with Diarrhea Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of Subjects with Fever Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of Subjects with Unsolicited AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9"/>
                    <measurement group_id="O2" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Unsolicited adverse events were recorded for each vaccine or placebo recipient from the day of vaccination through 28 days after vaccination or 28 days after challenge, whichever was later. SAEs and medically attended AEs were recorded through the end of the follow-up period (Day 181).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PVXV0200</title>
          <description>Biological: PXVX0200&#xD;
Single dose; liquid suspension after reconstitution with buffer; 5x10^8 CFU.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Biological: Placebo physiological saline</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <description>Placebo recipient 03019 developed potentially life-threatening hyperkalemia 3 days post-challenge and was considered unrelated to vaccination.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Placebo recipient 01047 was hospitalized for orthopedic surgery considered unrelated to vaccination.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Gastrointestinal sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Feeling Hot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Chlamydial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Upper Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Sports injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Cassie, Scientist, Clinical Research</name_or_title>
      <organization>Emergent BioSolutions Canada Inc.</organization>
      <phone>204-275-4589</phone>
      <email>dcassie@ebsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

